Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient.

Diagnostic microbiology and infectious disease - 1 May 2022

Sabin Arick P, Richmond Craig S, Kenny Paraic A

Abstract excerpt

The implementation of monoclonal antibody therapeutics during the COVID-19 pandemic altered the selective pressures encountered by SARS-CoV-2, raising the possibility of selection for resistant variants. Within-host viral evolution was reported in treated immunocompromised individuals but whether this signifies a real risk of onward transmission is unclear. We used a regional SARS-CoV-2 sequencing program to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19

Share to Mutation

Share to Pandemics

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 35231807
DOI: 10.1016/j.diagmicrobio.2022.115656
PMCID: PMC8810429

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient.PMID 35231807Read ↗

Acquisition and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patientSemantic proximity Read ↗

Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individualSemantic proximity Read ↗

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in GermanySemantic proximity Read ↗

Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.Semantic proximity Read ↗

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.Semantic proximity Read ↗

Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection.Semantic proximity Read ↗

Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapySemantic proximity Read ↗

Variant-specific humoral immune response to SARS-CoV-2 escape mutants arising in clinically severe, prolonged infectionSemantic proximity Read ↗

Complex intra-host SARS-CoV-2 evolution following monoclonal antibody pre-exposure prophylaxisSemantic proximity Read ↗

SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody MonotherapySemantic proximity Read ↗

SARS-CoV-2 evolution and immune escape in immunocompromised patients treated with exogenous antibodiesSemantic proximity Read ↗

Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.